Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Long-Term Deferred Tax: 2017

  • RedHill Biopharma's Long-Term Deferred Tax was N/A to $76.0 million in Q4 2017 from the same period last year, while for Dec 2017 it was $76.0 million, marking a year-over-year change of. This contributed to the annual value of $76.0 million for FY2017, which is N/A change from last year.
  • RedHill Biopharma's Long-Term Deferred Tax amounted to $76.0 million in Q4 2017.
  • RedHill Biopharma's Long-Term Deferred Tax's 5-year high stood at $76.0 million during Q4 2017, with a 5-year trough of $76.0 million in Q4 2017.
  • For the 1-year period, RedHill Biopharma's Long-Term Deferred Tax averaged around $76.0 million, with its median value being $76.0 million (2017).